Hookipa Pharma (HOOK) Coverage Initiated by Analysts at Svb Leerink

Svb Leerink initiated coverage on shares of Hookipa Pharma (NASDAQ:HOOK) in a research report sent to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $20.00 target price on the stock. Svb Leerink also issued estimates for Hookipa Pharma’s Q1 2019 earnings at ($0.55) EPS, Q2 2019 earnings at ($0.40) EPS, Q3 2019 earnings at ($0.48) EPS, Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($2.01) EPS, FY2020 earnings at ($1.98) EPS, FY2021 earnings at ($3.98) EPS, FY2022 earnings at ($3.15) EPS and FY2023 earnings at ($3.35) EPS.

Other analysts also recently issued research reports about the stock. Bank of America started coverage on shares of Hookipa Pharma in a research report on Monday. They set a buy rating and a $17.00 target price for the company. Royal Bank of Canada started coverage on shares of Hookipa Pharma in a research report on Monday. They set an outperform rating and a $23.00 target price for the company.

HOOK opened at $12.83 on Monday. Hookipa Pharma has a 1 year low of $12.30 and a 1 year high of $14.76.

In other news, insider Bros. Advisors Lp Baker acquired 892,857 shares of the stock in a transaction on Tuesday, April 23rd. The stock was bought at an average price of $14.00 per share, with a total value of $12,499,998.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sofinnova Capital Vi Fcpr acquired 357,142 shares of the stock in a transaction on Tuesday, April 23rd. The stock was purchased at an average cost of $14.00 per share, with a total value of $4,999,988.00. The disclosure for this purchase can be found here.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Read More: What are the components of an earnings report?

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.